Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Pulmonary Hypertension associated with Congenital Heart Disease

Author(s): Prashanth Venkatesh* and Erika B. Rosenzweig

Volume 20, Issue 3, 2024

Published on: 27 October, 2023

Page: [261 - 271] Pages: 11

DOI: 10.2174/011573398X269590231026103636

Price: $65

conference banner
Abstract

Pulmonary hypertension in patients with congenital heart disease is associated with significant mortality, morbidity and health services utilization. The predominant subtype of pulmonary hypertension in these patients is pulmonary arterial hypertension (PAH). PAH associated with congenital heart disease (PAH-CHD) comprises up to one-third of all PAH cases globally and is most commonly associated with anatomically simple shunt lesions. A myriad of clinical phenotypes of PAH-CHD are seen across the spectrum of shunt size, location and directionality. A conceptual framework to categorize these patients based on pathophysiology is described. Contemporary data regarding the management of the varied phenotypes are reviewed, and a novel algorithm to guide decision-making with shunt closure in patients with PAH-CHD is provided. Further data spanning the spectrum of basic, translational and clinical science are much needed to further inform the management of this highly complex and heterogeneous population.

Keywords: Pulmonary arterial hypertension, congenital heart disease, shunt, eisenmenger syndrome, pulmonary vasodilator, lung transplantation. 1. INTRODUCTION

« Previous Next »
[1]
Liu Y, Chen S, Zühlke L, et al. Global birth prevalence of congenital heart defects 1970–2017: Updated systematic review and meta-analysis of 260 studies. Int J Epidemiol 2019; 48(2): 455-63.
[http://dx.doi.org/10.1093/ije/dyz009] [PMID: 30783674]
[2]
Mandalenakis Z, Giang KW, Eriksson P, et al. Survival in children with congenital heart disease: Have we reached a peak at 97%? J Am Heart Assoc 2020; 9(22): e017704.
[http://dx.doi.org/10.1161/JAHA.120.017704] [PMID: 33153356]
[3]
Benziger CP, Stout K, Zaragoza-Macias E, Bertozzi-Villa A, Flaxman AD. Projected growth of the adult congenital heart disease population in the United States to 2050: An integrative systems modeling approach. Popul Health Metr 2015; 13(1): 29.
[http://dx.doi.org/10.1186/s12963-015-0063-z] [PMID: 26472940]
[4]
Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation 2014; 130(9): 749-56.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.008396] [PMID: 24944314]
[5]
Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120(2): 198-204.
[http://dx.doi.org/10.1016/j.ijcard.2006.09.017] [PMID: 17182132]
[6]
Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58(5): 538-46.
[http://dx.doi.org/10.1016/j.jacc.2011.03.033] [PMID: 21777753]
[7]
Schwartz SS, Madsen N, Laursen HB, Hirsch R, Olsen MS. Incidence and mortality of adults with pulmonary hypertension and congenital heart disease. Am J Cardiol 2018; 121(12): 1610-6.
[http://dx.doi.org/10.1016/j.amjcard.2018.02.051] [PMID: 29655882]
[8]
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53(1): 1801913.
[http://dx.doi.org/10.1183/13993003.01913-2018] [PMID: 30545968]
[9]
Freiberger A, Busse A, Ewert P, et al. Quality of life in adults with congenital heart disease with and without pulmonary hypertension: A comparative study. Cardiovasc Diagn Ther 2022; 12(6): 758-66.
[http://dx.doi.org/10.21037/cdt-22-284] [PMID: 36605070]
[10]
Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry. Chest 2010; 137(2): 376-87.
[http://dx.doi.org/10.1378/chest.09-1140] [PMID: 19837821]
[11]
Gall H, Felix JF, Schneck FK, et al. The giessen pulmonary hypertension registry: Survival in pulmonary hypertension subgroups. J Heart Lung Transplant 2017; 36(9): 957-67.
[http://dx.doi.org/10.1016/j.healun.2017.02.016] [PMID: 28302503]
[12]
Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39(4): 945-55.
[http://dx.doi.org/10.1183/09031936.00078411] [PMID: 21885399]
[13]
Spilimbergo FB, Pirath Rodrigues R, Credidio Dias-Pinto M, et al. Risk assessment validation in patients with pulmonary arterial hypertension: Data from a Southern Brazil registry (RESPHIRAR study). Pulm Circ 2023; 13(1): e12193.
[http://dx.doi.org/10.1002/pul2.12193] [PMID: 36968814]
[14]
Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(S25): D34-41.
[http://dx.doi.org/10.1016/j.jacc.2013.10.029] [PMID: 24355639]
[15]
French WJ, Chang P, Forsythe S, Criley JM. Estimation of mixed venous oxygen saturation. Cathet Cardiovasc Diagn 1983; 9(1): 25-31.
[http://dx.doi.org/10.1002/ccd.1810090105] [PMID: 6831550]
[16]
Miranda WR, Aboulhosn JA, Hagler DJ. Catheterization in adults with congenital heart disease. JACC Cardiovasc Interv 2022; 15(9): 907-21.
[http://dx.doi.org/10.1016/j.jcin.2021.12.020] [PMID: 35512915]
[17]
Eisenmenger V. Die angeborenen Defecte der Kammerscheide-wand des Herzens. Z Klin Med 1897; 32: 1-28.
[18]
Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ 1958; 2(5098): 701-9.
[http://dx.doi.org/10.1136/bmj.2.5098.701] [PMID: 13572874]
[19]
Marelli AJ, Aboulhosn JA. Perfloff’s Clinical Recognition of Congenital Heart Disease. (7th ed.), Elsevier Inc. 2023.
[20]
Craig RJ, Selzer A. Natural history and prognosis of atrial septal defect. Circulation 1968; 37(5): 805-15.
[http://dx.doi.org/10.1161/01.CIR.37.5.805] [PMID: 5646864]
[21]
Jiao K, Kulessa H, Tompkins K, et al. An essential role of Bmp4 in the atrioventricular septation of the mouse heart. Genes Dev 2003; 17(19): 2362-7.
[http://dx.doi.org/10.1101/gad.1124803] [PMID: 12975322]
[22]
Roberts KE, McElroy JJ, Wong WP, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004; 24(3): 371-4.
[http://dx.doi.org/10.1183/09031936.04.00018604] [PMID: 15358693]
[23]
Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: Comparative severity, correlates, and prognostic implication. Circulation 2005; 112(6): 828-35.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.529800] [PMID: 16061735]
[24]
Broberg CS, Valente AM, Huang J, et al. Myocardial fibrosis and its relation to adverse outcome in transposition of the great arteries with a systemic right ventricle. Int J Cardiol 2018; 271: 60-5.
[http://dx.doi.org/10.1016/j.ijcard.2018.04.089] [PMID: 30223379]
[25]
Oechslin E, Mebus S, Schulze-Neick I, et al. The adult patient with eisenmenger syndrome: A medical update after dana point part III: Specific management and surgical aspects. Curr Cardiol Rev 2010; 6(4): 363-72.
[http://dx.doi.org/10.2174/157340310793566127] [PMID: 22043213]
[26]
Chaix MA, Gatzoulis MA, Diller GP, Khairy P, Oechslin EN. Eisenmenger syndrome: A multisystem disorder—do not destabilize the balanced but fragile physiology. Can J Cardiol 2019; 35(12): 1664-74.
[http://dx.doi.org/10.1016/j.cjca.2019.10.002] [PMID: 31813503]
[27]
Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults. J Am Coll Cardiol 1999; 34(1): 223-32.
[http://dx.doi.org/10.1016/S0735-1097(99)00153-9] [PMID: 10400015]
[28]
Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121(1): 20-5.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.883876] [PMID: 20026774]
[29]
Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114(1): 48-54.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.630715] [PMID: 16801459]
[30]
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021; 42(6): 563-645.
[http://dx.doi.org/10.1093/eurheartj/ehaa554] [PMID: 32860028]
[31]
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43(38): 3618-731.
[http://dx.doi.org/10.1093/eurheartj/ehac237] [PMID: 36017548]
[32]
Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 2019; 139(14): e698-800.
[http://dx.doi.org/10.1161/CIR.0000000000000603] [PMID: 30586767]
[33]
Gatzoulis MA, Landzberg M, Beghetti M, et al. Evaluation of macitentan in patients with eisenmenger syndrome. Circulation 2019; 139(1): 51-63.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.033575] [PMID: 30586694]
[34]
Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99(14): 1858-65.
[http://dx.doi.org/10.1161/01.CIR.99.14.1858] [PMID: 10199883]
[35]
Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011; 6(5): 424-31.
[http://dx.doi.org/10.1111/j.1747-0803.2011.00561.x] [PMID: 21914136]
[36]
Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: A prospective, open-label, multicentre study. Heart 2011; 97(22): 1876-81.
[http://dx.doi.org/10.1136/heartjnl-2011-300344] [PMID: 21948962]
[37]
Rosenkranz S, Ghofrani HA, Beghetti M, et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart 2015; 101(22): 1792-9.
[http://dx.doi.org/10.1136/heartjnl-2015-307832] [PMID: 26135803]
[38]
D’Alto M, Romeo E, Argiento P, et al. Bosentan–sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012; 155(3): 378-82.
[http://dx.doi.org/10.1016/j.ijcard.2010.10.051] [PMID: 21081251]
[39]
Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010; 31(9): 1124-31.
[http://dx.doi.org/10.1093/eurheartj/ehq011] [PMID: 20202971]
[40]
D’Alto M, Constantine A, Balint OH, et al. The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome. Eur Respir J 2019; 54(5): 1901401.
[http://dx.doi.org/10.1183/13993003.01401-2019] [PMID: 31413162]
[41]
Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31(7): 1650-7.
[http://dx.doi.org/10.1016/S0735-1097(98)00162-4] [PMID: 9626847]
[42]
Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2008; 30(3): 256-65.
[http://dx.doi.org/10.1093/eurheartj/ehn597] [PMID: 19147605]
[43]
Gatzoulis MA, Webb GD, Daubeney PE, Eds. Diagnosis and Management of Adult Congenital Heart Disease. (2nd ed.), 2011.
[44]
Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: A combined retrospective and case-control study. Eur Heart J 2006; 27(14): 1737-42.
[http://dx.doi.org/10.1093/eurheartj/ehl116] [PMID: 16793921]
[45]
Kempny A, Hjortshøj CS, Gu H, et al. Predictors of death in contemporary adult patients with eisenmenger syndrome. Circulation 2017; 135(15): 1432-40.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.023033] [PMID: 27979875]
[46]
Gatzoulis MA, Beghetti M, Landzberg MJ, Galiè N. Pulmonary arterial hypertension associated with congenital heart disease: Recent advances and future directions. Int J Cardiol 2014; 177(2): 340-7.
[http://dx.doi.org/10.1016/j.ijcard.2014.09.024] [PMID: 25443244]
[47]
Reardon LC, Williams RJ, Houser LS, Miner PD, Child JS, Aboulhosn JA. Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger syndrome. Am J Cardiol 2012; 110(10): 1523-6.
[http://dx.doi.org/10.1016/j.amjcard.2012.06.061] [PMID: 22863176]
[48]
Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT, et al. Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. Int J Cardiol 2015; 184: 717-23.
[http://dx.doi.org/10.1016/j.ijcard.2015.02.031] [PMID: 25781723]
[49]
Moceri P, Dimopoulos K, Liodakis E, et al. Echocardiographic predictors of outcome in eisenmenger syndrome. Circulation 2012; 126(12): 1461-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.091421] [PMID: 22899772]
[50]
Hjortshøj CMS, Kempny A, Jensen AS, et al. Past and current cause-specific mortality in Eisenmenger syndrome. Eur Heart J 2017; 38(26): 2060-7.
[http://dx.doi.org/10.1093/eurheartj/ehx201] [PMID: 28430906]
[51]
Baroutidou A, Arvanitaki A, Hatzidakis A, et al. Haemoptysis in pulmonary arterial hypertension associated with congenital heart disease: Insights on pathophysiology, diagnosis and management. J Clin Med 2022; 11(3): 633.
[http://dx.doi.org/10.3390/jcm11030633] [PMID: 35160084]
[52]
Hjortshøj CS, Gilljam T, Dellgren G, et al. Outcome after heart–lung or lung transplantation in patients with Eisenmenger syndrome. Heart 2020; 106(2): 127-32.
[http://dx.doi.org/10.1136/heartjnl-2019-315345] [PMID: 31434713]
[53]
Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: A comparison between clinical subgroups. Eur Heart J 2014; 35(11): 716-24.
[http://dx.doi.org/10.1093/eurheartj/eht072] [PMID: 23455361]
[54]
Sertic F, Han J, Diagne D, et al. Not all septal defects are equal. Chest 2020; 158(5): 2097-106.
[http://dx.doi.org/10.1016/j.chest.2020.05.597] [PMID: 32565271]
[55]
Waddell TK, Bennett L, Kennedy R, Todd TRJ, Keshavjee SH. Heart–lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21(7): 731-7.
[http://dx.doi.org/10.1016/S1053-2498(01)00420-X] [PMID: 12100899]
[56]
Condliffe R, Clift P, Dimopoulos K, Tulloh RMR. Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ 2018; 8(3): 1-12.
[http://dx.doi.org/10.1177/2045894018792501] [PMID: 30033821]
[57]
Roth TS, Aboulhosn JA. Pulmonary hypertension and congenital heart disease. Cardiol Clin 2016; 34(3): 391-400.
[http://dx.doi.org/10.1016/j.ccl.2016.04.002] [PMID: 27443136]
[58]
Bradley EA, Ammash N, Martinez SC, et al. “Treat-to-close”: Non-repairable ASD-PAH in the adult. Int J Cardiol 2019; 291: 127-33.
[http://dx.doi.org/10.1016/j.ijcard.2019.03.056] [PMID: 31031077]
[59]
Takaya Y, Akagi T, Sakamoto I, et al. Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension. Heart 2022; 108(5): 382-7.
[http://dx.doi.org/10.1136/heartjnl-2021-319096] [PMID: 34415851]
[60]
Yan C, Pan X, Wan L, et al. Combination of F-ASO and targeted medical therapy in patients with secundum ASD and severe PAH. JACC Cardiovasc Interv 2020; 13(17): 2024-34.
[http://dx.doi.org/10.1016/j.jcin.2020.04.027] [PMID: 32800498]
[61]
Hu Z, Xie B, Zhai X, et al. Midterm results of “treat and repair” for adults with non-restrictive ventricular septal defect and severe pulmonary hypertension. J Thorac Dis 2015; 7(7): 1165-73.
[http://dx.doi.org/10.3978/j.issn.2072-1439.2015.07.06] [PMID: 26380732]
[62]
Mitropoulos FA, Apostolopoulou SC, Kanakis MA, Rammos S, Anagnostopoulos CE. Bosentan treatment in an adult with pulmonary hypertension due to patent ductus arteriosus permits surgical repair. J Heart Lung Transplant 2007; 26(12): 1345-6.
[http://dx.doi.org/10.1016/j.healun.2007.09.001] [PMID: 18096490]
[63]
Ebenroth ES, Hurwitz RA, Cordes TM. Late onset of pulmonary hypertension after successful Mustard surgery for d-transposition of the great arteries. Am J Cardiol 2000; 85(1): 127-30.
[http://dx.doi.org/10.1016/S0002-9149(99)00625-6]
[64]
Bravo-Jaimes K, Venkatesh P, Lluri G, et al. Temporary axial-flow mechanical circulatory support and intravenous treprostinil in a patient with D-transposition of the great arteries and atrial switch: A case report. Int J Cardiol Congenit Heart Dis 2022; 8: 100361.
[http://dx.doi.org/10.1016/j.ijcchd.2022.100361]
[65]
Kinsley RH, McGoon DC, Danielson GK, Wallace RB, Mair DD. Pulmonary arterial hypertension after repair of tetralogy of Fallot. J Thorac Cardiovasc Surg 1974; 67(1): 110-20.
[http://dx.doi.org/10.1016/S0022-5223(19)39765-X] [PMID: 4808906]
[66]
Chiu SN, Wang JK, Chen HC, et al. Long-term survival and unnatural deaths of patients with repaired tetralogy of Fallot in an Asian cohort. Circ Cardiovasc Qual Outcomes 2012; 5(1): 120-5.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.111.963603] [PMID: 22235069]
[67]
Kumar B, Puri GD, Manoj R, Gupta K, Shyam SK. Severe pulmonary artery hypertension following intracardiac repair of tetralogy of Fallot: An unusual finding. Pulm Circ 2011; 1(1): 115-8.
[http://dx.doi.org/10.4103/2045-8932.78099] [PMID: 22034598]
[68]
Alsaied T, Rathod RH, Aboulhosn JA, et al. Reaching consensus for unified medical language in Fontan care. ESC Heart Fail 2021; 8(5): 3894-905.
[http://dx.doi.org/10.1002/ehf2.13294] [PMID: 34190428]
[69]
Goldberg DJ, Zak V, Goldstein BH, et al. Results of the FUEL trial. Circulation 2020; 141(8): 641-51.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044352] [PMID: 31736357]
[70]
Cedars AM, Saef J, Peterson LR, et al. Effect of ambrisentan on exercise capacity in adult patients after the fontan procedure. Am J Cardiol 2016; 117(9): 1524-32.
[http://dx.doi.org/10.1016/j.amjcard.2016.02.024] [PMID: 27063478]
[71]
Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after fontan operation. Circulation 2014; 130(23): 2021-30.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.008441] [PMID: 25446057]
[72]
Wang W, Hu X, Liao W, et al. The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: A meta-analysis of randomized controlled trials. Pulm Circ 2019; 9(1): 1-9.
[http://dx.doi.org/10.1177/2045894018790450] [PMID: 29972332]

Rights & Permissions Print Cite
Article Metrics
13
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy